Efficacy and Safety of R-hLH (Luveris ®) Priming Prior to R-HFSH Treatment in Infertile Women Undergoing IVF-ET
Launched by NHS GREATER GLASGOW AND CLYDE · Feb 27, 2007
Trial Information
Current as of August 22, 2025
Completed
Keywords
ClinConnect Summary
Normal women undergoing IVF (Total n = 146; GRI n = 43) were recruited in 4 centres in 3 countries, and all were started on treatment with a depo GnRH-agonist to suppress endogenous gonadotropin secretion. Block randomisation lead to a distribution 71 untreated cases and 75 cases treated with rec-hLH (Luveris,\[Serono\]; 300IU/d) for 7 days. On the following days recombinant follicle stimulating hormone (rec-hFSH) stimulation of the ovaries was initiated using Gonal-f (150IU/d) for approximately 12 days.
HCG (3500IU) was given when \>2 mature follicles were seen by ovarian ultrasound, and ...
Gender
FEMALE
Eligibility criteria
- Inclusion Criteria:
- • infertile undergoing IVF
- • normal menstrual rhythm
- Exclusion Criteria:
- • polycystic ovaries
- • known resistance to FSH
- • other drug preparations
About Nhs Greater Glasgow And Clyde
NHS Greater Glasgow and Clyde (NHS GG&C) is one of the largest health organizations in the UK, dedicated to delivering high-quality healthcare services to a diverse population. As a clinical trial sponsor, NHS GG&C plays a pivotal role in advancing medical research and improving patient outcomes through innovative clinical studies. The organization is committed to upholding rigorous ethical standards and regulatory compliance, ensuring that all trials are conducted with the utmost care for participant safety and scientific integrity. With a focus on collaboration, NHS GG&C partners with academic institutions, healthcare professionals, and industry stakeholders to foster an environment conducive to groundbreaking research and the development of new therapies.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Odense, , Denmark
Paris, , France
Edinburgh, , United Kingdom
Patients applied
Trial Officials
Richard Fleming, PhD
Principal Investigator
NHS Greater Glasgow and Clyde
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials